UNLABELLED: The PET radioligand (11)C-CUMI-101 was previously suggested as a putative agonist radioligand for the serotonin 1A (5-hydroxytryptamine 1A [5-HT1A]) receptor in recombinant cells expressing human 5-HT1A receptor. However, a recent study showed that CUMI-101 behaved as a potent 5-HT1A receptor antagonist in rat brain. CUMI-101 also has moderate affinity (Ki = 6.75 nM) for α1 adrenoceptors measured in vitro. The current study examined the functional properties and selectivity of CUMI-101, both in vitro and in vivo. METHODS: The functional assay was performed using (35)S-GTPγS (GTP is guanosine triphosphate) in primate brains. The cross-reactivity of CUMI-101 with α1 adrenoceptors was performed using in vitro radioligand binding studies in rat, monkey, and human brains as well as in vivo PET imaging in mouse, rat, and monkey brains. RESULTS: CUMI-101 did not stimulate (35)S-GTPγS binding in primate brain, in contrast to 8-OH-DPAT, a potent 5-HT1A receptor agonist. Instead, CUMI-101 behaved as a potent 5-HT1A receptor antagonist by dose-dependently inhibiting 8-OH-DPAT-stimulated (35)S-GTPγS binding. Both in vitro and in vivo studies showed that CUMI-101 had significant α1 adrenoceptor cross-reactivity. On average, across all 3 species examined, cross-reactivity was highest in the thalamus (>45%) and lowest in the neocortex and cerebellum (<10%). PET imaging further confirmed that only preblocking with WAY-100635 plus prazosin decreased (11)C-CUMI-101 brain uptake to that of self-block. CONCLUSION: CUMI-101 behaves as a 5-HT1A receptor antagonist in primate brain, with significant, regional-dependent α1 adrenoceptor cross-reactivity, limiting its potential use as a PET radioligand in humans.
UNLABELLED: The PET radioligand (11)C-CUMI-101 was previously suggested as a putative agonist radioligand for the serotonin 1A(5-hydroxytryptamine 1A [5-HT1A]) receptor in recombinant cells expressing human5-HT1A receptor. However, a recent study showed that CUMI-101 behaved as a potent 5-HT1A receptor antagonist in rat brain. CUMI-101 also has moderate affinity (Ki = 6.75 nM) for α1 adrenoceptors measured in vitro. The current study examined the functional properties and selectivity of CUMI-101, both in vitro and in vivo. METHODS: The functional assay was performed using (35)S-GTPγS (GTP is guanosine triphosphate) in primate brains. The cross-reactivity of CUMI-101 with α1 adrenoceptors was performed using in vitro radioligand binding studies in rat, monkey, and human brains as well as in vivo PET imaging in mouse, rat, and monkey brains. RESULTS:CUMI-101 did not stimulate (35)S-GTPγS binding in primate brain, in contrast to 8-OH-DPAT, a potent 5-HT1A receptor agonist. Instead, CUMI-101 behaved as a potent 5-HT1A receptor antagonist by dose-dependently inhibiting 8-OH-DPAT-stimulated (35)S-GTPγS binding. Both in vitro and in vivo studies showed that CUMI-101 had significant α1 adrenoceptor cross-reactivity. On average, across all 3 species examined, cross-reactivity was highest in the thalamus (>45%) and lowest in the neocortex and cerebellum (<10%). PET imaging further confirmed that only preblocking with WAY-100635 plus prazosin decreased (11)C-CUMI-101 brain uptake to that of self-block. CONCLUSION:CUMI-101 behaves as a 5-HT1A receptor antagonist in primate brain, with significant, regional-dependent α1 adrenoceptor cross-reactivity, limiting its potential use as a PET radioligand in humans.
Authors: Lars H Pinborg; Ling Feng; Mette E Haahr; Nic Gillings; Agnete Dyssegaard; Jacob Madsen; Claus Svarer; Stig Yndgaard; Troels W Kjaer; Ramin V Parsey; Hanne D Hansen; Anders Ettrup; Olaf B Paulson; Gitte M Knudsen Journal: Synapse Date: 2012-07-20 Impact factor: 2.562
Authors: Mikael Palner; Mark D Underwood; Dileep J S Kumar; Victoria Arango; Gitte M Knudsen; J John Mann; Ramin V Parsey Journal: Synapse Date: 2011-03-21 Impact factor: 2.562
Authors: J S Dileep Kumar; Ramin V Parsey; Suham A Kassir; Vattoly J Majo; Matthew S Milak; Jaya Prabhakaran; Norman R Simpson; Mark D Underwood; J John Mann; Victoria Arango Journal: Brain Res Date: 2013-02-27 Impact factor: 3.252
Authors: Junli Chen; Ahsan K Murad; Laurence P G Wakelin; William A Denny; Renate Griffith; Angela M Finch Journal: Biochem Pharmacol Date: 2013-03-19 Impact factor: 5.858
Authors: Anu J Airaksinen; Sjoerd J Finnema; Thomas Balle; Katarina Varnäs; Benny Bang-Andersen; Balázs Gulyás; Lars Farde; Christer Halldin Journal: Nucl Med Biol Date: 2013-06-27 Impact factor: 2.408
Authors: S Selvaraj; F Turkheimer; L Rosso; P Faulkner; E Mouchlianitis; J P Roiser; P McGuire; P J Cowen; O Howes Journal: Mol Psychiatry Date: 2012-06-05 Impact factor: 15.992
Authors: Louise M Paterson; Birgitte R Kornum; David J Nutt; Victor W Pike; Gitte M Knudsen Journal: Med Res Rev Date: 2011-06-14 Impact factor: 12.944
Authors: Rajapillai L I Pillai; Elizabeth A Bartlett; Mala R Ananth; Chencan Zhu; Jie Yang; Greg Hajcak; Ramin V Parsey; Christine DeLorenzo Journal: Neuroimage Date: 2020-03-10 Impact factor: 6.556
Authors: Stal S Shrestha; Jeih-San Liow; Kimberly Jenko; Masamichi Ikawa; Sami S Zoghbi; Robert B Innis Journal: J Nucl Med Date: 2016-09-01 Impact factor: 10.057
Authors: J S Dileep Kumar; Mark D Underwood; Norman R Simpson; Suham A Kassir; Jaya Prabhakaran; Vattoly J Majo; Mihran J Bakalian; Ramin V Parsey; J John Mann; Victoria Arango Journal: ACS Med Chem Lett Date: 2016-03-13 Impact factor: 4.345
Authors: Sjoerd J Finnema; Mika Scheinin; Mohammed Shahid; Jussi Lehto; Edilio Borroni; Benny Bang-Andersen; Jukka Sallinen; Erik Wong; Lars Farde; Christer Halldin; Sarah Grimwood Journal: Psychopharmacology (Berl) Date: 2015-04-30 Impact factor: 4.530
Authors: Sudhakar Selvaraj; Chris Walker; Danilo Arnone; Bo Cao; Paul Faulkner; Philip J Cowen; Jonathan P Roiser; Oliver Howes Journal: Neuropsychopharmacology Date: 2017-08-04 Impact factor: 7.853